{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T11:32:00Z","timestamp":1751974320448},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40266-017-0444-z","type":"journal-article","created":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T08:48:10Z","timestamp":1488271690000},"page":"233-240","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Selecting Potential Pharmacological Interventions in Sarcopenia"],"prefix":"10.1007","volume":"34","author":[{"given":"Amanda J.","family":"Kilsby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avan A.","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles D.","family":"Witham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"key":"444_CR1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ajcn\/50.5.1231","volume":"50","author":"I Rosenberg","year":"1989","unstructured":"Rosenberg I. Summary comments. Am J Clin Nutr. 1989;50:1231\u20133.","journal-title":"Am J Clin Nutr"},{"key":"444_CR2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ageing\/afs191","volume":"42","author":"A Sayer","year":"2013","unstructured":"Sayer A, Robinson S, Patel H, et al. New horizons in the pathogenesis, diagnosis and management of sarcopenia. Age Ageing. 2013;42:145\u201350.","journal-title":"Age Ageing"},{"issue":"4","key":"444_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jocd.2015.04.009","volume":"18","author":"C Roberts","year":"2015","unstructured":"Roberts C, Dodds R, Sayer A. Current clinical care of older adults with sarcopenia. J Clin Densitom. 2015;18(4):193\u20138.","journal-title":"J Clin Densitom."},{"key":"444_CR4","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/jc.2014-3290","volume":"99","author":"M Grossmann","year":"2014","unstructured":"Grossmann M. Myostatin inhibition: a new treatment for androgen deprivation-induced sarcopenia? J Clin Endocrinol Metab. 2014;99:3625\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"444_CR5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1532-5415.2004.52014.x","volume":"52","author":"I Janssen","year":"2004","unstructured":"Janssen I, Shepard D, Katzmarzyk P, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52:80\u20135.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"444_CR6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/jpet.112.191759","volume":"343","author":"M Brotto","year":"2012","unstructured":"Brotto M, Abreu E. Sarcopenia: pharmacology of today and tomorrow. J Pharmacol Exp Ther. 2012;343(3):540\u20136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"444_CR7","first-page":"114","volume":"4","author":"M Cesari","year":"2015","unstructured":"Cesari M, Fielding R, Benichou O, et al. Pharmacological interventions in frailty and sarcopenia: report by the international conference on frailty and sarcopenia research task force. J Frailty Aging. 2015;4(3):114\u201320.","journal-title":"J Frailty Aging"},{"key":"444_CR8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"A Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft A, Baeyens J, Bauer J, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39:412\u201323.","journal-title":"Age Ageing"},{"key":"444_CR9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","volume":"12","author":"R Fielding","year":"2011","unstructured":"Fielding R, Vellas B, Evans W, et al. Sarcopenia: an undiagnosed condition in older adults. current consensus definition: prevalence, etiology, and consequences. international working group on sarcopenia. J Am Med Dir Assoc. 2011;12:249\u201356.","journal-title":"J Am Med Dir Assoc"},{"key":"444_CR10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/ageing\/afu115","volume":"43","author":"A Cruz-Jentoft","year":"2014","unstructured":"Cruz-Jentoft A, Landi F, Schneider S, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Intitiative (EWGSOP and IWGS). Age Ageing. 2014;43:748\u201359.","journal-title":"Age Ageing"},{"key":"444_CR11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bone.2015.08.011","volume":"80","author":"J Compston","year":"2015","unstructured":"Compston J, Fearon K. Emerging therapeutic concepts for muscle and bone preservation\/formation. Bone. 2015;80:157\u201361.","journal-title":"Bone"},{"key":"444_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1096\/fj.03-0610com","volume":"18","author":"S Lecker","year":"2004","unstructured":"Lecker S, Jagoe R, Gilbert A, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004;18:39\u201351.","journal-title":"FASEB J"},{"key":"444_CR13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(02)08024-8","volume":"359","author":"G Onder","year":"2002","unstructured":"Onder G, Penninx B, Balkrishnan R, et al. Relation between use of angiotensin converting enzyme inhibitors and muscle strenght and physical function in older women: an observational study. Lancet. 2002;359:926\u201330.","journal-title":"Lancet"},{"issue":"1","key":"444_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/1745509X.4.1.37","volume":"4","author":"C Carter","year":"2008","unstructured":"Carter C, Groban L. Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction. Aging Health. 2008;4(1):37\u201346.","journal-title":"Aging Health"},{"issue":"5","key":"444_CR15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1590\/0004-273000000","volume":"58","author":"R Dodds","year":"2014","unstructured":"Dodds R, Sayer A. Sarcopenia. Arq Bras Endocrinol Metabol. 2014;58(5):464\u20139.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"23","key":"444_CR16","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","volume":"114","author":"J George","year":"2006","unstructured":"George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508\u201316.","journal-title":"Circulation"},{"issue":"3","key":"444_CR17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/ageing\/aft046","volume":"42","author":"L Beveridge","year":"2013","unstructured":"Beveridge L, Ramage L, McMurdo M, et al. Allopurinol use is associated with greater functional gains in older rehabilitation patients. Age Ageing. 2013;42(3):400\u20134.","journal-title":"Age Ageing"},{"issue":"12","key":"444_CR18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/j.1532-5415.2009.02566.x","volume":"57","author":"J Woo","year":"2009","unstructured":"Woo J, Leung J, Sham A, et al. Defining sarcopenia in terms of risk of physical limitations: a 5-year follow-up study of 3,153 Chinese men and women. J Am Geriatr Soc. 2009;57(12):2224\u201331.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"444_CR19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s12603-009-0209-4","volume":"13","author":"G Onder","year":"2009","unstructured":"Onder G, Della Vedova C, Landi F. Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia. J Nutr Health Aging. 2009;13(8):746\u201356.","journal-title":"J Nutr Health Aging"},{"key":"444_CR20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ageing\/afp203","volume":"39","author":"T Ashfield","year":"2010","unstructured":"Ashfield T, Syddall H, Martin H, et al. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. Age Ageing. 2010;39:185\u201391.","journal-title":"Age Ageing"},{"issue":"3","key":"444_CR21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MCO.0b013e3282fa1810","volume":"11","author":"V Guasconi","year":"2008","unstructured":"Guasconi V, Puri P. Epigentic drugs in the treatment of skeletal muscle atrophy. Curr Opin Clin Nutr Metab Care. 2008;11(3):233\u201341.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"4","key":"444_CR22","first-page":"487","volume":"11","author":"K Tsuchida","year":"2008","unstructured":"Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel. 2008;11(4):487\u201394.","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"12","key":"444_CR23","first-page":"948","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker C, Lord S, Studenski S, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet. 2015;3(12):948\u201357.","journal-title":"Lancet"},{"issue":"1","key":"444_CR24","first-page":"22","volume":"12","author":"S Budui","year":"2015","unstructured":"Budui S, Rossi A, Zamboni M. The pathogenetic basis of sarcopenia. Clin Cases Miner Bone Metab. 2015;12(1):22\u20136.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"3","key":"444_CR25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cger.2011.03.010","volume":"27","author":"G Abellan van Kan","year":"2011","unstructured":"Abellan van Kan G, Cameron Chulmea W, Gillette-Guyonet S, et al. Clinical trials on sarcopenia: methodological issues regarding phase 3 trials. Clin Geriatr Med. 2011;27(3):471\u201382.","journal-title":"Clin Geriatr Med"},{"key":"444_CR26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jcsm.12051","volume":"6","author":"R Calvani","year":"2015","unstructured":"Calvani R, Marini F, Cesari M, et al. Biomarkers for physical frailty and sarcopenia: state of the science and future developments. J Cachexia Sarcopenia Muscle. 2015;6:278\u201386.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"444_CR27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000435853","volume":"62","author":"J Erusalimsky","year":"2016","unstructured":"Erusalimsky J, Grillari J, Grune T, et al. In search of \u2018omics\u2019-based biomarkers to predict risk of frailty and its consequences in older individuals: the FRAILOMIC initiative. Gerontology. 2016;62(2):182\u201390.","journal-title":"Gerontology"},{"key":"444_CR28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40520-015-0517-y","volume":"28","author":"J Reginster","year":"2016","unstructured":"Reginster J, Cooper C, Rozzili R et al. Recommendations for the registration of drugs to treat sarcopenia. Aging Clin Exp Res. 2016;28;47\u201358.","journal-title":"Aging Clin Exp Res."},{"key":"444_CR29","first-page":"CD002759","volume":"3","author":"C Liu","year":"2009","unstructured":"Liu C, Latham N. Progressive resistance strength training for improving physical function in older adults: systematic review. Cochrane Database Syst Rev. 2009;3:CD002759.","journal-title":"Cochrane Database Syst Rev"},{"key":"444_CR30","doi-asserted-by":"crossref","first-page":"E1967","DOI":"10.1210\/jc.2014-1271","volume":"99","author":"D Padhi","year":"2014","unstructured":"Padhi D, Higano C, Shore N, et al. Pharmacologic inhibition of myostatin and changes in lean body mass and lower extremity size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2014;99:E1967\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"444_CR31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89\u201395.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"444_CR32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13539-013-0120-z","volume":"5","author":"M Fragala","year":"2014","unstructured":"Fragala M, Jajtner A, Beyer K, et al. Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. J Cachexia Sarcopenia Muscle. 2014;5(2):139\u201348.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"444_CR33","first-page":"129","volume":"2","author":"S Berry","year":"2013","unstructured":"Berry S, Ramachandran V, Cawthon P, et al. Procollagen type II N-terminal peptide (P3NP) and lean mass: a cross-sectional study. J Frailty Aging. 2013;2:129\u201334.","journal-title":"J Frailty Aging"},{"key":"444_CR34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.exger.2014.10.003","volume":"60","author":"E Marzetti","year":"2014","unstructured":"Marzetti E, Calvani R, Lorenzi M, et al. Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fracture patients. Exp Gerontol. 2014;60:79\u201382.","journal-title":"Exp Gerontol"},{"issue":"8","key":"444_CR35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s12603-009-0200-0","volume":"13","author":"G Abellan Van Kan","year":"2009","unstructured":"Abellan Van Kan G, Andre E, Bischoff-Ferrari H, et al. Carla task force on sarcopenia: propositions for clinical trials. J Nutr Health Aging. 2009;13(8):700\u20137.","journal-title":"J Nutr Health Aging"},{"issue":"4","key":"444_CR36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s13244-015-0414-0","volume":"6","author":"C Yip","year":"2015","unstructured":"Yip C, Dinkel C, Mahajan A, et al. Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015;6(4):489\u201397.","journal-title":"Insights Imaging"},{"issue":"10","key":"444_CR37","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.biocel.2013.06.016","volume":"45","author":"V Baracos","year":"2013","unstructured":"Baracos V, Kazemi-Bajestani S. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol. 2013;45(10):2302\u20138.","journal-title":"Int J Biochem Cell Biol"},{"issue":"12","key":"444_CR38","doi-asserted-by":"crossref","first-page":"23878","DOI":"10.3390\/ijms151223878","volume":"15","author":"G Loncar","year":"2014","unstructured":"Loncar G, Omersa D, Cvetinovic N, et al. Emerging biomarkers in heart failure and cardiac cachexia. Int J Mol Sci. 2014;15(12):23878\u201396.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"444_CR39","first-page":"123","volume":"4","author":"M Pahor","year":"2015","unstructured":"Pahor M. Mobility and functional outcomes for sarcopenia trials. J Frailty Aging. 2015;4(3):123\u20134.","journal-title":"J Frailty Aging"},{"key":"444_CR40","unstructured":"Burton L, Sumukadas D, Witham M et al. Does spironolactone improve exercise capactiy in functionally impaired older people without heart failure? [abstract]. In: British Geriatrics Society Autumn Meeting, 12\u201314 Oct 2011. Brighton Centre. Brighton: British Geriatrics Society; 2011. Abstr no. 2."},{"key":"444_CR41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13063-015-0631-3","volume":"16","author":"R Dennis","year":"2015","unstructured":"Dennis R, Ponnappan U, Kodell R, et al. Immune function and muscle adaptations to resistance exercise in older adults: study protocol for a randomized control trial of a nutritional supplement. Trials. 2015;16:121.","journal-title":"Trials"},{"issue":"2","key":"444_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cct.2008.10.005","volume":"30","author":"N LeBrasseur","year":"2009","unstructured":"LeBrasseur N, Lajevardi N, Miciek R, et al. Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM trial): design and methods. Contemp Clin Trials. 2009;30(2):133\u201340.","journal-title":"Contemp Clin Trials"},{"key":"444_CR43","doi-asserted-by":"crossref","unstructured":"LIFE Study investigators, Pahor M, Blair SN, Espeland M, et al. Effects of a physical activity intervention on measures of physical performance: results of the Lifestyle Interventions and Independence for Elders Pilot (LIFE-P) Study. J Gerontol A Biol Sci Med Sci. 2006;61(11):1157\u20131165.","DOI":"10.1093\/gerona\/61.11.1157"},{"issue":"2","key":"444_CR44","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.archger.2013.10.008","volume":"58","author":"B Oh","year":"2014","unstructured":"Oh B, Cho B, Choi H-C, et al. The influence of lower-extremity function in elderly individuals\u2019 quality of life (QOL): an analysis of the correlation between SPPB and EQ-5D. Arch Gerontol Geriatr. 2014;58(2):278\u201382.","journal-title":"Arch Gerontol Geriatr"},{"issue":"6","key":"444_CR45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/ageing\/afv133","volume":"44","author":"C Beaudart","year":"2015","unstructured":"Beaudart C, Biver E, Reginster J, et al. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing. 2015;44(6):960\u20136.","journal-title":"Age Ageing"},{"key":"444_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw192","author":"C Beaudart","year":"2016","unstructured":"Beaudart C, Edwards M, Moss C, et al. English translation and validation of the SarQoL\u00ae, a quality of life questionnaire specific for sarcopenia. Age Ageing 2016. doi: 10.1093\/ageing\/afw192","journal-title":"Age Ageing"},{"key":"444_CR47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ageing\/afn124","volume":"37","author":"MW Witham","year":"2008","unstructured":"Witham MW, Sumukadas D, McMurdo ME. ACE inhibitors for sarcopenia\u2014as good as exercise training? Age Ageing. 2008;37:363\u20135.","journal-title":"Age Ageing"},{"issue":"6","key":"444_CR48","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/gerona\/glt142","volume":"69","author":"D Sumukadas","year":"2014","unstructured":"Sumukadas D, Band M, Miller S, et al. Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2014;69(6):736\u201343.","journal-title":"J Gerontol A Biol Sci Med Sci"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-017-0444-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T05:03:11Z","timestamp":1568869391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-017-0444-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1007\/s40266-017-0444-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}